BEIJING, Sept. 15 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced the initiation of clinical trials in Ukraine for its inactivated hepatitis A vaccine, Healive, in September, 2008. The trials are being conducted by Biolik Biopharmaceutical Company, a vaccine manufacturer located in Kharkov, Ukraine to seek regulatory approval in the Country. Biolik will also market and distribute Healive in Ukraine, which has an estimated market opportunity of up to $10 million.
The clinical trials are expected to enroll approximately 300 adults and 200 children with dosing and follow-up occurring over a six month period. The Companies anticipate that it will take approximately nine to twelve months to complete the trial and receive regulatory approval.
Mr. Weidong Yin, Chairman, President and CEO, commented, "As a developer of world-class vaccines, our strategy has been to provide high quality vaccines to people around the world. Sinovac is continuing to pursue strategic distribution partnerships that enable us to enter attractive markets outside of China by leveraging our GMP-certified manufacturing capabilities, which are capable of providing low cost, highly scalable production. We look forward to seeing the Ukrainian market contribute to our sales growth."
"Biolik" is well known in Ukraine and ex-USSR as the manufacturer of
many immunobiological and medicinal products. Its products are delivered to
all regions of Ukraine, Russia and countries of the Commonwealth of
Independent States. Biolik constantly focuses on the modernization of
manufacturing and improvement of technological schemes. Industrial shops
and sites that meet international standards are commissioned annually.
Today, Biolik is the only enterprise in Ukraine that manufactures vaccines
for prophylaxis of diphtheria, tetanus and pertussis. Additional
information about Biolik is available on its website,
|SOURCE Sinovac Biotech Ltd.|
Copyright©2008 PR Newswire.
All rights reserved